Scientists say substandard proteins, some of which appear to split apart inside the body, can provoke the rare clots
Venous Thromboembolic Event Rates Up With ChAdOx1-S Vaccine
However, absolute risks are small, with 11 excess venous thromboembolic events per 100,000 vaccinations
Guidance Issued for Managing CVST After COVID-19 Vaccination
CVST with thrombocytopenia reported after COVID-19 vaccine with adenoviral vector; management similar to heparin-induced thrombocytopenia
12 Cases of CVST Reported for Ad26.COV2.S Vaccine in the U.S.
Time from vaccination to symptom onset varied from six to 15 days; initial presentation was headache in 11 cases
FDA Moves to Resume Use of J&J COVID Vaccine
Johnson & Johnson has agreed with the U.S. Food and Drug Administration to add a warning label to the vaccine
J&J COVID-19 Vaccine Should Be Used, but Carry Blood Clot Warning
European Medicines Agency also said the vaccine’s benefits still far outweigh its risks
CDC Panel Says It Needs More Time to Study J&J Vaccine Clotting Cases
Advisers to the CDC say they do not have enough information or time to recommend how to proceed and they will meet again within 10 days
Rare Thrombosis, Thrombocytopenia Seen After AstraZeneca COVID-19 Vaccine
Reports document 16 reactions in young European patients following first dose of ChAdOx1 nCoV-19 vaccine
FDA, CDC Call for Pause in J&J COVID-19 Vaccine After Six People Develop Clots
The six cases involved a cerebral venous sinus thrombosis and occurred in women between the ages of 18 and 48 years
Blood Clot Risk High Following COVID-19 Hospitalization
However, anticoagulation cuts risk for major thromboembolic events by 46 percent
- Page 1 of 2
- 1
- 2